2,3-二氧代吲哚啉-5-甲酸 | 25128-32-9

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2,3-二氧代吲哚啉-5-甲酸
• 中文别名: 2,3-二氧代吲哚啉-5-羧酸
• 英文名称: 5-carboxyisatin
• 英文别名: 2,3-dioxoindoline-5-carboxylic acid；2,3-dioxo-1H-indole-5-carboxylic acid
• CAS: 25128-32-9
• 化学式: C₉H₅NO₄
• mdl: MFCD00967204
• 分子量: 191.143
• InChiKey: SNPPWTIGLNZFRF-UHFFFAOYSA-N

物化性质

• 熔点：
  295 °C(Solv: acetic acid (64-19-7))
• 密度：
  1.591±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,3-Dioxoindoline-5-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,3-Dioxoindoline-5-carboxylic acid
CAS number: 25128-32-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H5NO4
Molecular weight: 191.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氧代吲哚啉-5-甲酸 在 hydrazine hydrate 作用下， 生成 5-羧基吲哚-2-酮
  参考文献：
  名称：

  Synthesis, anti-lung cancer activity and molecular docking study of 3-methylene-2-oxoindoline-5-carboxamide derivatives

  摘要：

  A series of 3-methylene-2-oxoindoline-5-carboxamide derivatives were synthesized in appreciable yield by using 4-aminobenzoic acid as a starting material. The preliminary biological test results showed that most compounds displayed potent inhibitory activity against proliferation of human lung adenocarcinoma epithelial cell line (A549) in MTT assay. Compound 6l displayed the highest potency (IC50 = 3.0 mu M). The western blot analysis demonstrated a correlation between anti-proliferative activity of active compounds and blockade of the phosphorylation of extracellular signal-regulated kinases (ERK1/2). The docking study also provides new insights into further optimization of 3-methylene-2-oxoindoline-5-carboxamide derivatives for the discovery of more potent RAF/MEK/ERK pathway regulators as anti-lung cancer agents.

  DOI：

  10.1007/s00044-017-2050-3
• 作为产物：
  描述：

  5-三氟甲基靛红 在 氢溴酸 作用下， 生成 2,3-二氧代吲哚啉-5-甲酸
  参考文献：
  名称：

  Derivatives of o-, m- and p-Aminobenzotrifluoride¹

  摘要：

  DOI：

  10.1021/ja01152a009

文献信息

• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER
  申请人：PELEMED CO., LTD.

  公开号：US20200270229A1

  公开（公告）日：2020-08-27

  The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer, comprising, as an active ingredient, an indirubin derivative. When the compound of the present invention is used, it can effectively inhibit the activity of FLT3 kinase and can be usefully used to prevent or treat acute myeloid leukemia or metastatic breast cancer.

  本发明涉及一种用于预防或治疗急性髓样白血病或转移性乳腺癌的药物组合物，其包括一种因地鲁宾衍生物作为活性成分。当使用本发明的化合物时，可以有效抑制FLT3激酶的活性，并可用于预防或治疗急性髓样白血病或转移性乳腺癌。
• Synthesis and Biological Evaluation of Quinoline Salicylic Acids As P-Selectin Antagonists
  作者：Neelu Kaila、Kristin Janz、Silvano DeBernardo、Patricia W. Bedard、Raymond T. Camphausen、Steve Tam、Desirée H. H. Tsao、James C. Keith、Cheryl Nickerson-Nutter、Adam Shilling、Ruth Young-Sciame、Qin Wang

  DOI：10.1021/jm0602256

  日期：2007.1.1

  junctions into the underlying tissue. The initial rolling step is mediated by the interaction of leukocyte glycoproteins containing active moieties such as sialyl Lewisx (sLex) with P-selectin expressed on endothelial cells. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of inflammatory diseases such as arthritis

  白细胞炎症和组织损伤部位的募集涉及白细胞沿内皮壁滚动，然后白细胞牢固粘附，最后白细胞跨细胞连接转运到下面的组织中。初始滚动步骤由包含活性部分的白细胞糖蛋白（如唾液酸化的Lewisx（sLex））与在内皮细胞上表达的P-选择蛋白的相互作用介导。因此，借助于小分子P-选择蛋白拮抗剂抑制这种相互作用是治疗炎性疾病如关节炎的有吸引力的策略。惠氏化学文库的高通量筛选确定了喹啉水杨酸类化合物（1）作为P-选择素的拮抗剂，其体外和基于细胞的测定方法的功效远远优于sLex。通过迭代药物化学，我们鉴定出具有改善的P-选择素活性，减少的二氢Orate脱氢酶抑制作用和可接受的CYP谱的类似物。铅化合物36在类风湿关节炎的大鼠AIA模型中有效。
• Identification and further development of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B
  作者：Viktor V. Vintonyak、Karin Warburg、Björn Over、Katja Hübel、Daniel Rauh、Herbert Waldmann

  DOI：10.1016/j.tet.2011.04.026

  日期：2011.9

  biologically active component. The reported MptpB inhibitors show excellent selectivity against a selected panel of protein tyrosine phosphatases, including MptpA (M. tuberculosis protein tyrosine phosphatase A), PTP1B (protein tyrosine phosphatase 1B), SHP-2 (Src homology 2 domain-containing protein tyrosine phosphatase), PTPN2, h-PTPβ (human protein tyrosine phosphatase β), and VHR (Vaccinia virus VH1-related

  结核病仍然是全世界发病率和死亡率的主要原因。从蛋白酪氨酸磷酸酶结核分枝杆菌是由于它们在细胞内生存发展的作用在对抗结核病的新策略有吸引力的目标结核分枝杆菌的各种感染模型。在这里，我们报道了与吲哚啉酮-2螺环稠合的噻唑烷酮类化合物的鉴定和进一步开发，这是一类新型的结核分枝杆菌蛋白酪氨酸磷酸酶B的有效和选择性抑制剂。详细的结构-活性关系（SAR）研究表明：硝基取代的2-氧吲哚核与二卤代苯胺和卤代N-苄基部分对于针对MptpB（结核分枝杆菌蛋白酪氨酸磷酸酶B）的强抑制活性是必不可少的。所鉴定化合物的小结构修饰导致化合物溶解度和细胞渗透性的显着改善，从而在微摩尔范围内保持抑制活性。发现螺中心的构型对于抑制活性是至关重要的，并且外消旋物的分离显示出R -（-）-对映异构体是生物活性成分。报道的MptpB抑制剂对选定的一组蛋白酪氨酸磷酸酶（包括MptpA（结核分枝杆菌）蛋白酪氨酸磷酸酶A），PTP1B（
• 对SARS冠状病毒主蛋白酶具有抑制作用的靛 红-5-酰胺类抑制剂
  申请人：天津市国际生物医药联合研究院

  公开号：CN103159665B

  公开（公告）日：2017-01-25

  本发明提供式(1)所示的靛红‑5‑酰胺类化合物，所述化合物具有SARS冠状病毒主蛋白酶抑制活性，可以用作SARS冠状病毒主蛋白酶抑制剂，在SARS治疗中发挥作用，式(1)化合物结构式如下：。
• 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
  申请人：PELEMED CO., LTD. 주식회사 펠레메드(120190402315) Corp. No ▼ 110111-7125845BRN ▼319-81-01407

  公开号：KR20210047850A

  公开（公告）日：2021-04-30

  본 발명은 인디루빈 유도체를 유효 성분으로 포함하는 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물에 관한 것이다. 본 발명의 조성물을 이용하는 경우 FLT3 키나아제의 활성을 효과적으로 억제하고, 급성 골수성 백혈병 또는 전이성 유방암을 예방 또는 치료하는데 유용하게 사용할 수 있다.

  This invention relates to a pharmaceutical composition for the prevention or treatment of acute myeloid leukemia or metastatic breast cancer, which includes an indirubin derivative as an active ingredient. When using the composition of the present invention, it can effectively inhibit the activity of FLT3 kinase and be useful for preventing or treating acute myeloid leukemia or metastatic breast cancer.